U-LABA/ICS Effects on Exercise Performance, Formoterol

Morten Hostrup, PhD20 enrolled

Overview

The purpose of the project is to investigate exercise performance in well-trained individuals in a crossover design following varying degrees of bronchodilation/constriction intervention using current standard procedures.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

QUADRUPLE

Enrollment

Conditions

Exercise Performance

Interventions

SymbicortDRUG

Participants are administered 54 μg Formoterol and 1920 μg Budesonide

FormoterolDRUG

Participants are administered 54 μg Formoterol from an inhaler device

FormoterolDRUG

Participants are administered 120 μg Formoterol in a capsule, which is taken orally

Eligibility

Sex: ALLMin age: 18 YearsMax age: 45 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Age 18-45 * Physically active \>5 hours a week * Maximum oxygen uptake classified as high or very high Exclusion Criteria: * Diagnosed with severe asthma and been in treatment with long-acting beta2-agonist/corticosteroid * ECG abnormality * FEV1/FVC ratio \< 0,7 determined with spirometry * Chronic illness determined to be a potential risk for participant during the study * In chronic treatments with medication that may interfere with study results * Pregnancy * Smoker * Blood donation during the past 3 months

Locations (1)

August Krogh Building

Copenhagen, Denmark

Outcomes

Primary Outcomes

Power output during time trial

Mean power output measured in Watts during a time trial on a bike ergometer

Time frame: Through study completion, an average on 4 weeks

Secondary Outcomes

Power output during sprint testing

Power output measured in Watts during a sprint on a bike ergometer

Time frame: Through study completion, an average on 4 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.